Northern Development is a Norwegian/Australian based company developing a next generation heart assist device, targeting a major population Heart Failure patients who currently have no treatment option, the HFpEF population. This population, HFpEF or diastolic heart failure, represents a total sales potential of more than EUR 5 billions. The PulseVad technlogy will also represent major benefits for the current HFrEF market, a market today dominated by Medtronic and Abbott. The HFpEF population is fast growing and is expected to pass the current LVAD population (HFrEF/systoiic heart failure), HFrEF, by 2020 and where the younger population is growing fastest. Northern Development has developed PulseVad, a new, sensor-based pump, allowing for treatment of HFpEF patients, as the first company. Pre Clinicals estimated to start Q3 2019, First in Man planned for December 2020. PulseVad will be the first assist device to enter the HFpEF market, and have several technological break throughs including intelligent sensors, minimal invasive implantation system, implantable controller and offers adaptive blood supply for the patients. The key components in system have finalized prototypes and been tested in bench and animal models. Valuation of the company is expected to be high and exit options multiple by 2021,Northern Development is a Norwegian/Australian based company developing a next generation heart assist device, targeting a major population Heart Failure patients who currently have no treatment option, the HFpEF population. This population, HFpEF or diastolic heart failure, represents a total sales potential of more than EUR 5 billions. The PulseVad technlogy will also represent major benefits for the current HFrEF market, a market today dominated by Medtronic and Abbott. The HFpEF population is fast growing and is expected to pass the current LVAD population (HFrEF/systoiic heart failure), HFrEF, by 2020 and where the younger population is growing fastest. Northern Development has developed PulseVad, a new, sensor-based pump, allowing for treatment of HFpEF patients, as the first company. Pre Clinicals estimated to start Q3 2019, First in Man planned for December 2020. PulseVad will be the first assist device to enter the HFpEF market, and have several technological break throughs including intelligent sensors, minimal invasive implantation system, implantable controller and offers adaptive blood supply for the patients. The key components in system have finalized prototypes and been tested in bench and animal models. Valuation of the company is expected to be high and exit options multiple by 2021